We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
Cap. Flow
-$141M
Cap. Flow %
-5.14%
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$60.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$57M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$40M
4
WBA
Walgreens Boots Alliance
WBA
+$31.6M
5
GMED icon
Globus Medical
GMED
+$26.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$102M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$40.6M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23.8M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$20.7M
5
HCA icon
HCA Healthcare
HCA
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 46.9%
2 Financials 2.94%
3 Technology 0.55%
4 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCRX
101
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.26M 0.08%
461,119
+200,000
+77% +$1.15M
PARN
102
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$2.2M 0.08%
+382,645
New +$2.3M
WGBS
103
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.98M 0.07%
+91,040
New +$2.03M
PTN
104
Palatin Technologies
PTN
$16.2M
$1.86M 0.07%
1,600
– –
KND
105
DELISTED
Kindred Healthcare
KND
$1.81M 0.07%
+93,100
New +$2.03M
VIRX
106
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.6M 0.06%
1,065
-1,343
-56% -$1.94M
EXEL icon
107
CALL
Exelixis
EXEL
$14.1B
$1.53M 0.06%
1,000,000
– –
TEAR
108
DELISTED
TearLab Corporation
TEAR
$1.2M 0.04%
+35,410
New +$1.5M
SEM
109
DELISTED
Select Medical
SEM
$1.15M 0.04%
176,916
+18,003
+11% +$139K
SLXP
110
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$914K 0.03%
+5,850
New +$848K
WCG
111
DELISTED
Wellcare Health Plans, Inc.
WCG
$905K 0.03%
+15,000
New +$995K
AXGN icon
112
Axogen
AXGN
$2.12B
$842K 0.03%
+345,000
New +$842K
AGRX
113
DELISTED
Agile Therapeutics
AGRX
$767K 0.03%
53
+1
+2% +$15.4K
OPK icon
114
Opko Health
OPK
$899M
$638K 0.02%
75,000
+37,500
+100% +$330K
PRTA icon
115
Prothena Corp
PRTA
$453M
$609K 0.02%
27,500
+7,500
+38% +$159K
HMSY
116
DELISTED
HMS Holdings Corp.
HMSY
$553K 0.02%
+29,316
New +$593K
SGMO
117
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$539K 0.02%
+50,000
New +$653K
IRWD icon
118
Ironwood Pharmaceuticals
IRWD
$635M
$475K 0.02%
+43,764
New +$501K
PRPO icon
119
Precipio
PRPO
$44M
$260K 0.01%
8
– –
ELOS
120
DELISTED
Syneron Medical Ltd
ELOS
$139K 0.01%
+13,893
New +$141K
IMRS
121
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
$88K ﹤0.01%
147,076
-260,316
-64% -$226K
ALNY icon
122
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-100,000
Closed -$6.32M
AMED
123
DELISTED
Amedisys
AMED
– –
-81,399
Closed -$1.36M
AZN icon
124
AstraZeneca
AZN
$262B
– –
-12,500
Closed -$929K
HUM icon
125
Humana
HUM
$48B
– –
-114,448
Closed -$14.5M
3 4
5
6 7

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2014 Portfolio in Review

As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.

  • Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
  • Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
  • Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
  • Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
  • Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.

Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.